Triad Eye Institute Pllc | |
3131 Military Blvd, Muskogee, OK 74401-2290 | |
(918) 687-6600 | |
(918) 307-1983 |
Full Name | Triad Eye Institute Pllc |
---|---|
Type | Facility |
Speciality | Ophthalmology |
Location | 3131 Military Blvd, Muskogee, Oklahoma |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1447382833 | NPI | - | NPPES |
CO5028 | Other | OK | RAILROAD MEDICARE |
490004258 | Other | OK | RAILROAD MEDICARE |
100738620D | Medicaid | OK | |
490000830 | Other | OK | RAILROAD MEDICARE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
152W00000X | Optometrist | 731288036 (Oklahoma) | Secondary |
207W00000X | Ophthalmology | 731288036 (Oklahoma) | Primary |
Mailing Address | Practice Location Address |
---|---|
Triad Eye Institute Pllc 6140 S Memorial Dr, Tulsa, OK 74133-1933 Ph: (918) 252-2020 | Triad Eye Institute Pllc 3131 Military Blvd, Muskogee, OK 74401-2290 Ph: (918) 687-6600 |
News Archive
The renowned online scientific journal JoVE videos study experiments with the aim of improving the reproducibility of biomedical experiments.
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, announced today that it has entered into a definitive agreement to acquire Valtech Cardio, Ltd.
Glycated hemoglobin (HbA1c) is well recognized as a reliable measure for glycemic control.
Removing branding and wrapping cigarettes in plain packaging helps remove the appeal of smoking according to new a Cancer Research UK-funded study published in Tobacco Control.
Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), time to progression, and disease control rate in non-small cell lung cancer (NSCLC) patients who have relapsed or failed two or three previous treatment regimens.
› Verified 4 days ago